STAT July 11, 2024
A few years back, TIGIT was hailed as the next blockbuster target for cancer immunotherapy. Based on early data, drugmakers were hopeful that blocking two checkpoint proteins on immune cells — TIGIT and PD-1/PD-L1 — would be more effective at killing tumors than just blocking one, potentially offering greater benefit...